泰国国家解毒剂项目实施前后氰化物中毒分析
该研究为回顾性队列,分析2007年1月1日至2015年12月31日报告至Ramathibodi中毒中心的343例氰化物或氰苷摄入中毒病例。国家解毒剂项目(NAP)实施后(213例)较实施前(130例)解毒剂使用率升高(39.9% vs 24.6%),适当使用率升高(74.1% vs 50.0%)。总体死亡率无差异(实施前13例[10.0%] vs 实施后17例[8.0%])。在80例初始严重症状者中,NAP和适当使用解毒剂降低死亡率(OR 0.327,95%CI 0.106-0.997;OR 0.024,95%CI 0.004-0.122),多因素分析中二者独立降低死亡风险(OR 0.122,95%CI 0.023-0.633;OR 0.034,95%CI 0.007-0.167)。
要点
- 在初始严重症状的80例中,适当使用解毒剂(正确指征、正确剂量方案、90分钟内给药)降低死亡率(OR 0.024,95%CI 0.004-0.122)。
- NAP实施后解毒剂使用率39.9% vs 实施前24.6%,适当使用率74.1% vs 50.0%。
- 全部30例死亡均表现为初始严重症状。
- 氰化物化学来源与自杀意图与死亡相关(OR 12.919,95%CI 4.863-39.761;OR 10.747,95%CI 3.884-28.514)。
- 总体死亡率实施前13例(10.0%) vs 实施后17例(8.0%),无差异。
适用人群与场景
- 2007年1月1日至2015年12月31日报告至Ramathibodi中毒中心的氰化物或氰苷摄入中毒病例,共343例。
- NAP实施后(Project组)213例(62.1%),实施前(Before组)130例(37.9%)。
诊断标准与关键阈值
- 适当使用解毒剂定义为正确指征、正确剂量方案、90分钟内给药。
红旗征与不能漏的情况
- 初始严重症状:全部30例死亡均表现为初始严重症状。
- 氰化物化学来源与自杀意图与死亡相关(OR 12.919,95%CI 4.863-39.761;OR 10.747,95%CI 3.884-28.514)。
研究设计与关键结果
- 研究类型:回顾性队列;样本量343例;人群:氰化物或氰苷摄入中毒病例;干预:NAP实施(Project组) vs 实施前(Before组)。
- 主要终点:总体死亡率实施前13例(10.0%) vs 实施后17例(8.0%),无差异。
- 解毒剂使用率Project组39.9% vs Before组24.6%;适当使用率Project组74.1% vs Before组50.0%。
- 亚组分析(80例初始严重症状):NAP降低死亡率(OR 0.327,95%CI 0.106-0.997);适当使用解毒剂降低死亡率(OR 0.024,95%CI 0.004-0.122)。
- 多因素分析(初始严重症状者):NAP独立降低死亡风险(OR 0.122,95%CI 0.023-0.633);适当使用解毒剂独立降低死亡风险(OR 0.034,95%CI 0.007-0.167),调整暴露意图、氰化物来源、年龄和性别。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在氰化物或氰苷摄入中毒且初始出现严重症状的患者中,实施NAP和适当使用解毒剂与死亡率降低相关。
- 适当使用解毒剂包括正确指征、正确剂量方案和90分钟内给药。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: Antidote shortage is a global problem. In Thailand, the National Antidote Project (NAP) has operated since November 2010 to manage the national antidote stockpile, educate the healthcare providers on appropriate antidote use, and evaluate antidote usage.
OBJECTIVE: To evaluate the effect of NAP implementation on mortality rate and antidote use in cyanide poisoning cases arising from ingestion of cyanide or cyanogenic glycoside.
METHODS: This is a retrospective cohort of poisoning cases involving cyanide or cyanogenic glycoside ingestion reported to Ramathibodi Poison Center from 1 January 2007 to 31 December 2015. Mortality rate, antidote use, and appropriateness of antidote use (defined as correct indication, proper dosing regimen, and administration within 90 min) before and after NAP implementation were compared. Association between parameters and fatal outcomes was analyzed.
RESULTS: A total of 343 cases involving cyanide or cyanogenic glycoside ingestion were reported to Ramathibodi Poison Center. There were 213 cases (62.1%) during NAP (Project group) and 130 cases (37.9%) pre-NAP implementation (Before group). Implementation of NAP led to increased antidote use (39.9% in Project group versus 24.6% in Before group) and a higher rate of appropriate antidote use (74.1% in Project group versus 50.0% in Before group). All 30 deaths were presented with initial severe symptoms. Cyanide chemical source and self-harm intent were associated with death (OR: 12.919, 95% CI: 4.863-39.761 and OR: 10.747, 95% CI: 3.884-28.514, respectively). No difference in overall mortality rate (13 [10.0%] deaths before versus 17 [8.0%] deaths after NAP) was found. In subgroup analysis of 80 cases with initial severe symptoms, NAP and appropriate antidote use reduced mortality (OR: 0.327, 95% CI: 0.106-0.997 and OR: 0.024, 95% CI: 0.004-0.122, respectively). In the multivariate analysis of the cases with initial severe symptoms, presence of the NAP and appropriate antidote use independently reduced the risk of death (OR: 0.122, 95% CI: 0.023-0.633 and OR: 0.034, 95% CI: 0.007-0.167, respectively), adjusted for intent of exposure, cyanide source, age, and sex.
CONCLUSIONS: After NAP implementation, both antidote use and appropriate antidote use increased. In cases presenting with severe symptoms, presence of the NAP and appropriate antidote use independently reduced the risk of mortality.
参考来源
- Srisuma S, Pradoo A, Rittilert P, et al. Cyanide poisoning in Thailand before and after establishment of the National Antidote Project. Clin Toxicol (Phila). 2017. PMID: 28871819. doi:10.1080/15563650.2017.1370098
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。